Oncimmune, a cancer detection spinout from Nottingham University, held its initial public offering on Aim, London’s alternative investment market, shortly before its CFO passed away.
The company has developed an autoantibody test that can be used for the early detection of cancer.
Though the initial public offering Oncimmune raised gross proceeds of £11m at 130p per share. This gives the company a market capitalisation of approximately £66.3m.
The company is trading under the ticker symbol of ONC.L.
As of writing…
